rises, while that of potassium falls. Both acetazolamide and spironolactone are said to be of prophylactic value against mountain sickness, though the mechanism of their action is unknown, and that of spironolactone must be mediated by a mechanism unrelated to aldosterone antagonism. Whether the use of these drugs lessens proteinuria at altitude remains to be studied. Pines found haematuria (as detected by BiliLabstix) in some of his subjects, which is further suggestive evidence of direct renal damage at altitude.
Acute hypoxia seems, then, in some way to lead to loss of protein in the urine. With acclimatisation this loss lessens but does not disappear. Apparently chronic hypoxia, whether due to tesidence at high altitude or to a right-to-left intracardiac shunt, has the same effect. Since, however, the extent of the proteinuria so caused is small and neither causes hypoproteinaemia nor otherwise threatens health, there can be no justification for taking renal biopsy samples from volunteers in high-altitude laboratories-and the morphological appearances of the kidney exposed to rapid ascent to high altitude may therefore remain unknown. There is no reason to believe that the kidney is the prime cause of the various manifestations of mountain sickness; probably the sequence of events set in train by progressive hypoxia and hyperventilation affects the kidney along with other organs. Chest, 1978, 72, 196. 3Rennie, I D B, and Joseph, B, Lancet, 1970, 1, 1247. 4 Rennie, I D B, et al,JYouirnal of Applied Physiology, 1971, 31, 257. Cancer after cardiac transplantation The striking increase in the incidence of lymphoid neoplasms in patients who have transplants is intriguing but unexplained. Recent reports' 2 from workers at Stanford have left no doubt that the increased risk is not restricted to renal transplantation and that there is a similar raised incidence of these neoplasms in patients who have had cardiac transplants. The first report by Krikorian and his colleagues' gave details on all 124 patients who underwent cardiac transplantation at the Stanford University Medical Center between January 1968 and April 1977. The median survival of these patients was 18 months, and, of the 35 deaths which occurred over three months after transplantation, four were due to malignant disease: two lymphomas, one acute myeloid leukaemia, and one adenocarcinoma of the colon. In addition, there was another case of lymphoma and two cases of squamous carcinoma of the skin among the survivors at the end of the study period. These seven cases contrast with an expected number of 04 in a normal population. No differences were detected in the frequency of rejection episodes or in the HLA compatibility of the graft in patients with lymphomas when compared with other patients.
A later report from the same centre by Anderson et a12 gave information on an additional 19 patients, bringing the total studied to 143, and extended the follow-up to June 1978, by which time no fewer than six patients had developed lymphoma. This second report discussed several risk factors that had been undetected in the earlier study. In particular, the risk of lymphoma among recipients of cardiac transplants was found to be higher than after renal transplantation. This difference was entirely due to the very high risk of lymphomas in patients whose primary disease had been cardiomyopathy. The other risk factor was young age at transplantation. In fact, all six patients with lymphoma had had cardiomyopathy and were aged less than 40 years.
Several hypotheses have been put forward to account for the excess of lymphoid neoplasia in patients who have had transplants, and these have recently been well reviewed by Hoover.3 They included impaired "immunosurveillance," chronic uraemia (itself immunosuppressive), the chemical carcinogenicity of immunosuppressive drugs, oncogenic viruses, chronic antigenic stimulation, and graft-versus-host reactions-or a combination of some of these factors. The fact that by no means all types of malignancy are increased in incidence argues against a simple interpretation of the concept of impaired immunosurveillance, while the unusually short induction period of these neoplasms makes the chemical carcinogenicity of the living standards due to their relatively low remuneration. It asks for a completely new charter to be negotiated to ensure that the average net remuneration of a general practitioner be comparable with the medical remuneration in countries in the EEC."' Dr Ball and his colleagues could have constructed a straightforward pay claim (with examples of highly paid European doctors), camouflaged it with some fine-sounding medicopolitical phrases, and presented the package to an enthusiastic LMC Conference last year. Fortunately for the future of general practice they chose a harsher road, emphasising their first main objective as "the welfare of our patients" and their second as "the well being and unity of general practitioners, without which the attainment of the first objective would be jeopardised." The generally favourable reception accorded the report and its authors by the GMS Committee last week (p 568) showed that the committee members, too, were as concerned about the future standards of general practice as they were about the decline in GPs' living standards. This is the right attitude for a profession.
Fifteen years ago general practice faced a severe crisis: it was saved by the 1965 Family Doctor Charter,2 which signalled a revolution not only by providing substantially more pay for GPs but also by changing to a system of payment that encouraged doctors to provide better surgery premises and more supporting staff, to increase their postgraduate training, and to take more time off. The result was an increase in the numbers of general practitioners, a restoration of morale, a great improvement in professional status, and an impetus for the development of undergraduate and postgraduate training, which culminated in the Vocational Training Act.3 Nevertheless, the social and economic pressures on the Health Service in the past five years or so have threatened to undermine some of the first charter's successes.
Was this threat to be countered by another radical change in the way primary care was given and paid for or did the medicopolitical circumstances, so different from the 1965 confrontation with the Government, dictate an evolutionary solution ? After studying the extensive evidence given to it the working group decided against revolution. It has opted for preserving the general principles of the present contract, including the all important independent contractor status (a protection against bureaucracy for patients as well as GPs), while proposing that remuneration be more closely related to the family doctor's work load than now, especially his out-of-hours responsibilities, and calling for a big reduction in the average list size, to 1700, to allow GPs more time to see their patients.
So there are no radical proposals for charging patients or for introducing a salaried service, which will disappoint minorities within the profession. There may also be some GPs who will be disappointed that Dr Ball's working group have acknowledged unequivocally that "the family doctor recognises his professional and ethical responsibility to his patients of providing continuing care." But this obligation, the report points out, is distinct from the contractual commitments of the NHS. So it is proposed that the new contract would contain basic commitment payments related to service in normal working hours and supplementary payments which would include fee-for-service payments for out-of-hours work, with higher rates for "out-of-bed" and weekend duties. Furthermore, the working group argue in favour of a narrower definition of average net remuneration-the Review Body's annual target recommendation for GPs-by excluding those Serzvice, 1965. 3National Health Service (Vocational Trainti?ng) Act 1976 . London, HMSO, 1976 .
